BioCentury
ARTICLE | Clinical News

Salford study reveals real-world asthma outcomes

May 6, 2017 1:11 AM UTC

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Innoviva Inc. (NASDAQ:INVA) said Relvar Ellipta fluticasone furoate/vilanterol met the primary endpoint in the Phase III Salford Lung Study to treat asthma. The study is GSK’s second real-world outcomes trial evaluating Relvar Ellipta, which it markets to treat asthma and chronic obstructive pulmonary disease (COPD). It is known as Breo Ellipta in the U.S.

GSK began designing the pragmatic real-world trials in 2008, well before Relvar Ellipta’s approval in any indication. The company has said the studies are meant to provide evidence to patients and payers on how the treatment works outside the artificial construct of a randomized clinical trial (see BioCentury, Sept. 5, 2016)...